JP2012526544A5 - - Google Patents

Info

Publication number

JP2012526544A5

JP2012526544A5 JP2012510423A JP2012510423A JP2012526544A5 JP 2012526544 A5 JP2012526544 A5 JP 2012526544A5 JP 2012510423 A JP2012510423 A JP 2012510423A JP 2012510423 A JP2012510423 A JP 2012510423A JP 2012526544 A5 JP2012526544 A5 JP 2012526544A5

Authority

JP

Japan

Prior art keywords

pde4d7

expression

prostate cancer

sample

level

Prior art date

2010-05-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 206010060862 Prostate cancer Diseases 0.000 claims 31
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 31
• 239000005556 hormone Substances 0.000 claims 30
• 229940088597 hormone Drugs 0.000 claims 30
• 230000003211 malignant effect Effects 0.000 claims 26
• 108090000623 proteins and genes Proteins 0.000 claims 26
• 239000000523 sample Substances 0.000 claims 23
• 102000004169 proteins and genes Human genes 0.000 claims 19
• 238000000034 method Methods 0.000 claims 14
• 238000012544 monitoring process Methods 0.000 claims 12
• 239000008194 pharmaceutical composition Substances 0.000 claims 11
• 238000003018 immunoassay Methods 0.000 claims 10
• 230000000694 effects Effects 0.000 claims 9
• 108020004707 nucleic acids Proteins 0.000 claims 7
• 102000039446 nucleic acids Human genes 0.000 claims 7
• 150000007523 nucleic acids Chemical class 0.000 claims 7
• 150000001875 compounds Chemical class 0.000 claims 6
• 230000002401 inhibitory effect Effects 0.000 claims 6
• 206010004385 Benign neoplasm of prostate Diseases 0.000 claims 5
• 239000003112 inhibitor Substances 0.000 claims 5
• 239000003446 ligand Substances 0.000 claims 5
• 239000000203 mixture Substances 0.000 claims 5
• 206010028980 Neoplasm Diseases 0.000 claims 4
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 4
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 4
• 201000011510 cancer Diseases 0.000 claims 4
• 238000010324 immunological assay Methods 0.000 claims 4
• 108091070501 miRNA Proteins 0.000 claims 4
• 239000002679 microRNA Substances 0.000 claims 4
• 230000004936 stimulating effect Effects 0.000 claims 4
• 108091023037 Aptamer Proteins 0.000 claims 3
• 102000004190 Enzymes Human genes 0.000 claims 3
• 108090000790 Enzymes Proteins 0.000 claims 3
• 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 3
• 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 3
• 239000013068 control sample Substances 0.000 claims 3
• 210000001519 tissue Anatomy 0.000 claims 3
• 108091005461 Nucleic proteins Proteins 0.000 claims 2
• 108020004459 Small interfering RNA Proteins 0.000 claims 2
• 239000005557 antagonist Substances 0.000 claims 2
• 230000000692 anti-sense effect Effects 0.000 claims 2
• 230000004071 biological effect Effects 0.000 claims 2
• 230000003247 decreasing effect Effects 0.000 claims 2
• 238000001514 detection method Methods 0.000 claims 2
• 239000003550 marker Substances 0.000 claims 2
• 239000000816 peptidomimetic Substances 0.000 claims 2
• 108090000765 processed proteins & peptides Proteins 0.000 claims 2
• 210000002307 prostate Anatomy 0.000 claims 2
• 230000035945 sensitivity Effects 0.000 claims 2
• 150000003384 small molecules Chemical class 0.000 claims 2
• 238000012360 testing method Methods 0.000 claims 2
• 210000002700 urine Anatomy 0.000 claims 2
• 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
• 108700039887 Essential Genes Proteins 0.000 claims 1
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 1
• 101001067140 Homo sapiens Porphobilinogen deaminase Proteins 0.000 claims 1
• 108091034117 Oligonucleotide Proteins 0.000 claims 1
• 102100034391 Porphobilinogen deaminase Human genes 0.000 claims 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
• 239000000556 agonist Substances 0.000 claims 1
• 230000003281 allosteric effect Effects 0.000 claims 1
• 238000001574 biopsy Methods 0.000 claims 1
• 239000008280 blood Substances 0.000 claims 1
• 210000004369 blood Anatomy 0.000 claims 1
• 238000002512 chemotherapy Methods 0.000 claims 1
• 239000002872 contrast media Substances 0.000 claims 1
• 238000013480 data collection Methods 0.000 claims 1
• 239000012649 demethylating agent Substances 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 210000001808 exosome Anatomy 0.000 claims 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 1
• 230000036210 malignancy Effects 0.000 claims 1
• 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 238000001959 radiotherapy Methods 0.000 claims 1
• 230000000306 recurrent effect Effects 0.000 claims 1
• 210000003296 saliva Anatomy 0.000 claims 1
• 239000013049 sediment Substances 0.000 claims 1
• 210000000582 semen Anatomy 0.000 claims 1
• 238000006467 substitution reaction Methods 0.000 claims 1